PT  - JOURNAL ARTICLE
AU  - Marcia C Castro
AU  - Susie Gurzenda
AU  - Cassio M Turra
AU  - Sun Kim
AU  - Theresa Andrasfay
AU  - Noreen Goldman
TI  - Reduction in the 2020 Life Expectancy in Brazil after COVID-19
AID  - 10.1101/2021.04.06.21255013
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.06.21255013
4099  - http://medrxiv.org/content/early/2021/04/09/2021.04.06.21255013.short
4100  - http://medrxiv.org/content/early/2021/04/09/2021.04.06.21255013.full
AB  - Brazil has the second-largest number of COVID-19 deaths worldwide. We use data on reported deaths to measure and compare the death toll across states from a demographic perspective. We estimate a decline in 2020 life expectancy at birth of 1.94 years, resulting in a mortality level not seen since 2013. The reduction in life expectancy at age 65 was 1.58 years, setting Brazil back to 2009 levels. The decline was larger for males, widening by 2.3% and 5.4% the female-male gap in life expectancy at birth and at age 65, respectively. Among states, Amazonas lost 59.6% of the improvements in life expectancy at birth since 2000. With 2021 COVID-19 deaths at about 43% of the total 2020 figures (as of mid-March) the demographic effect is likely to be even higher this year.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHarvard TH Chan School of Public Health (MCC research funds)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Since data were de-identified, this study did not involve human subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and code required to reproduce the results in this article can be found on Zenodo (available upon acceptance).